Detalles de la búsqueda
1.
Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix.
Proc Natl Acad Sci U S A;
121(17): e2321898121, 2024 Apr 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38625939
2.
Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas.
Gynecol Oncol;
187: 12-20, 2024 May 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38703673
3.
Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer.
Gynecol Oncol;
2024 Feb 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38493021
4.
Integrated mutational landscape analysis of uterine leiomyosarcomas.
Proc Natl Acad Sci U S A;
118(15)2021 04 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-33876771
5.
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
Ann Surg Oncol;
30(9): 5597-5609, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37358686
6.
Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma.
Gynecol Oncol;
168: 157-165, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36442427
7.
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression.
Gynecol Oncol;
170: 38-45, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36610380
8.
The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo.
Gynecol Oncol;
170: 172-178, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36706643
9.
Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor.
Gynecol Oncol;
169: 98-105, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36525930
10.
Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor.
Gynecol Oncol;
172: 65-71, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36958197
11.
A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability.
Cancer;
128(6): 1206-1218, 2022 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34875107
12.
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
Br J Cancer;
126(12): 1695-1703, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35149854
13.
Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu.
Gynecol Oncol;
166(2): 351-357, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35641325
14.
Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.
Gynecol Oncol;
166(1): 117-125, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35599167
15.
Endometrial Sampling for Preoperative Diagnosis of Uterine Leiomyosarcoma.
J Minim Invasive Gynecol;
29(1): 119-127, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34265441
16.
Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors.
Proc Natl Acad Sci U S A;
116(2): 619-624, 2019 01 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30584090
17.
Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy.
Proc Natl Acad Sci U S A;
116(45): 22730-22736, 2019 11 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31624127
18.
Randomized trial of exercise on depressive symptomatology and brain derived neurotrophic factor (BDNF) in ovarian cancer survivors: The Women's Activity and Lifestyle Study in Connecticut (WALC).
Gynecol Oncol;
161(2): 587-594, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33773809
19.
Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu.
Gynecol Oncol;
163(1): 93-99, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34372971
20.
DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo.
Gynecol Oncol;
163(2): 334-341, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34452746